Baudo F, de Cataldo F, Mostarda G, Ghirarduzzi A, Molinatti M, Pengo V, Poli D, Tosetto A, Tiraferri E, Morra E
Thrombosis and Hemostasis Unit, Niguarda Hospital, Milan, Italy.
Intern Emerg Med. 2007 Dec;2(4):280-4. doi: 10.1007/s11739-007-0078-y. Epub 2007 Nov 28.
In the perioperative management of patients on long-term oral anticoagulant (OAC) therapy the problem is balancing the thromboembolic (TER) and the haemorrhagic risk (HR) in the perioperative period. The Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) activated an online registry from November 2001 to August 2003 in order to collect information on the management of these patients in Italy. Four hundred and eleven patients, undergoing elective major (18%) and minor surgery (82%), from 7 centres, were registered. Three hundred and ninety-nine out of 411 patients received LMWH either once a day (310 patients) or twice a day (89 patients) during OAC therapy discontinuation. Two thromboembolic (0.48%) and 16 bleeding events (7 major; 1.7%) were reported. Notwithstanding the lower doses of heparin (54.3 U/kg o.d. and 64.4 U/kg b.i.d.), the thromboembolic complications are in line with those reported in the literature. The data of this study suggest that the intervention with LMWH may be relevant only in the high-risk patients as already proposed by others.
对于长期接受口服抗凝剂(OAC)治疗的患者,围手术期管理的问题在于平衡围手术期的血栓栓塞风险(TER)和出血风险(HR)。意大利血栓形成诊断与抗血栓治疗监测中心联盟(FCSA)于2001年11月至2003年8月启动了一项在线登记,以收集意大利这些患者管理方面的信息。来自7个中心的411例患者接受了择期大手术(18%)和小手术(82%)并被登记。411例患者中有399例在停用OAC治疗期间接受了低分子肝素(LMWH)治疗,其中310例患者每天一次,89例患者每天两次。报告了2例血栓栓塞事件(0.48%)和16例出血事件(7例为大出血;1.7%)。尽管肝素剂量较低(每日54.3 U/kg及每日两次64.4 U/kg),但血栓栓塞并发症与文献报道的相符。本研究数据表明,正如其他人已经提出的那样,低分子肝素干预可能仅对高危患者有意义。